Search

everythinglearnresearchcommunity

for

Search:↓

The conversation discusses the delay in bringing FAK inhibitors and Stanford's hydrogel to market for hair transplants, with a preference for FAK inhibitors over Verteporfin due to their superior potential in preventing scarring. The user expresses frustration over the slow progress and hopes for faster development by companies like FAKnostics.

The conversation is about frustration over the delay in phase 2 results for a hair loss treatment called GT20029. One user suspects the treatment may have failed.

Amplifica is testing a compound called AMP-303 for hair loss, but it's not Scube3 or osteopontin. The timing for the results from the clinical trial is unknown.

The conversation discusses a clinical trial for Setipiprant in the US, starting June 29th, with eligibility excluding recent users of minoxidil or finasteride. It encourages informed decision-making before signing up.

A new human trial using an FDA-approved treatment for wound healing called Verteporfin, which may potentially be able to reverse scarring and regrow hair in that area. The trial is only lasting one month so far.

A trial of verteporfin for hair regeneration, with pictures comparing the original and current status, as well as links to other resources discussing the efficacy of this treatment in combination with Minoxidil, Finasteride, and RU58841.

A user warns against buying the Koreabeautics V2 microneedling pen, claiming it's marketed through fake success stories and is overpriced. Another user shares their experience, acknowledging the pen's quality but agreeing it's too expensive and reliant on frequent needle head replacements.

Shiseido's hair loss treatment reported only 5% regrowth, disappointing many. Users discussed other treatments like Minoxidil, finasteride, RU58841, and CB-03-01 as potential alternatives.

The user is considering another hair transplant or scalp micropigmentation (SMP) for a congenital bald spot, but previous transplants were less effective due to scar tissue. Suggestions include using hair fibers, changing hairstyles, or doing nothing, as the spot is not very noticeable.

A user plans to experiment with creating new hair follicles using methods like derma rolling, applying lithium chloride, tannic acid, and various other substances including caffeine, ketoconazole, and raspberry ketones. They also consider using anti-inflammatories, immunosuppressants, and DHT inhibitors to potentially improve results.

The conversation discusses using PGE2 as a hair growth stimulant, comparing it to minoxidil, and considering the addition of Setipiprant. Concerns about side effects like skin damage and cost are also mentioned.

A user is participating in a phase 3 trial for Clascoterone, a topical acne medication that may stimulate hair growth, and will share results after 6 months. They will have a section of their hair shaved and marked with a tattoo for the study.

Creatine may affect hair loss by reducing PGE2 levels, which could influence hair growth. The discussion highlights the need for more research on this potential mechanism.

Hair follicle regenerative therapy is being developed, with clinical trials planned in Japan, potentially allowing for hair cloning and eliminating the need for treatments like finasteride. If successful, the treatment could be available in Japan by 2025, but widespread access and affordability may take longer.

Tretinoin and microneedling both enhance hair growth through different mechanisms, with microneedling being considered safe for long-term use. Optimal microneedling needle length varies, but 0.8 mm is suggested for hair growth, and a Dermastamp is recommended to avoid skin damage.

Researching the effects of scalp trauma on hair growth, with some users suggesting experimenting with a soldering iron or derma pen, and others bringing up studies that suggest this may be an effective treatment.

Emerging hair loss treatments like PP405, a topical MPC inhibitor, show promise in activating stem cells for hair growth. The conversation seeks information on the development stages and accessibility of these treatments.

The user is dissatisfied with their hair transplant results from Asli Tarcan, citing poor donor area management and insufficient graft density. They advise against opting for cheaper procedures and express hope for future hair cloning solutions.

Oral PTD-DBM was discussed as a potential hair loss treatment, but it was deemed ineffective in humans despite promising results in mice. The conversation concluded that trying it without VPA might be unwise.

The post discusses the completion of the HMI-115 Australian Phase 1 Trial for hair loss treatment. The user speculates about the potential early release of the trial results.

TGF-B affects hair growth, both causing stem cell division and death depending on amounts. Amplifica's treatment injects Scube3 to increase TGF-B for hair growth.

Pelage Pharmaceuticals announced positive Phase 2a trial results for PP405 in hair loss therapy. The conversation discusses the delay in publishing full results and the need for further trials and approvals.

A stem cell and adenosine triphosphate cocktail showed promising results in hair regrowth for male and female mice, with potential for future clinical trials. Users humorously reacted to the success in mice, expressing hope for human application.

Fatty acid metabolic signaling can activate epithelial stem cells for hair regeneration. Oleic and palmitoleic acids showed the best results, but practical application on humans remains uncertain.

A human trial of verteporfin, a potential treatment for hair loss, with some users noting potential improvements in scarring and overall healing compared to control areas.

PP405 is likely fake, and JXL069 is an unrefined prototype with unknown side effects. It's advised to wait for the official PP405 release.

A user discusses their experience with at-home microneedling at 1mm for hair growth, feeling like they're hitting their skull. Other users suggest lowering the needle depth or stopping due to discomfort.

PP405 is a potential hair loss treatment undergoing trials, with discussions on its effectiveness and comparison to existing treatments like finasteride and minoxidil. There is skepticism about its status as a cure, with hopes for future advancements in genetic treatments like CRISPR.

The conversation discusses concerns that Anagenic's version of GT20029 might not be as effective or safe as Kintor's, with comparisons to issues faced by pyrilutamide. The chemical structure of the drug has been published.

The conversation discusses the correct method of microneedling for hair loss, questioning whether it should be done on areas with long hair without risking hair damage, and if it's necessary for improving blood flow to existing hair. No specific treatments were mentioned.